November 30, 2013

Opposition to Sofosbuvir Patent in India




Sofosbuvir is a pipeline hepatitis C (HCV) drug that has been recommended for treatment by the US FDA and EMA. HCV is a significant public health issue for low- and middle-income countries, that are home to 90% of the 185 million people who are infected with HCV. Although HCV is curable, high drug prices make treatment inaccessible, leaving people at risk for liver cancer or liver failure.

I-MAK filed an opposition against Gilead/Pharmasset's patent applications because we believe that the technologies comprising these patent applications are known and therefore undeserving of a patent grant. We also believe that it is now time that People Living with HCV obtain affordable access to the drugs they need.

Legal Documents for Opposition to Sofosbuvir (India)

I-MAK's Pre-Grant Opposition To The Prodrug Application (Without Exhibits)

I-MAK's Pre-Grant Opposition To The Prodrug Application (With Exhibits)

Background Information

MSF Press Release

Pricing Information And Speculation

Treatment Action Group: HIV, HCV And TB Pipeline Report

Media Coverage

'Indian Health Activists Move To Prevent Gilead’s Drug Patent' - Financial Times

'Hepatitis C Drug: US Group Opposes Gilead’s Patent Request In India' - Hindu Business Line

'Gilead Attempt To Secure Patent On Hepatitis C Drug Opposed In India' - Times Of India

'US Group Seeks To Block Gilead Drug Patent In India' - Yahoo News

Except for publications commissioned or published by third parties all content on this site is licensed under a Creative Commons Attribution 3.0 License


No comments:

Post a Comment